Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis

NCT03718884 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT03718884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03718884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
October 23, 2018
Completion date
October 28, 2019
Enrollment
29 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis